Truist analyst Joon Lee lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $90 and keeps a Buy rating on the shares. The company’s restructuring underway should help extend its operational runway into the first half of FY27 as NTLA-2002 is poised to be the historic first in vivo genome editing therapeutic to launch in 2027 for HAE, the analyst tells investors in a research note. Intellia’s Phase 3 MOMENTUM-1 enrollment is also ahead of schedule with 550 of planned 765 by 2025-end, the firm added. Truist notes however that given the evolving competitive dynamics in the ATTR – transthyretin amyloidosis – the firm is further lowering the penetration assumptions.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics: Promising Potential in Biotech with NTLA-2002 Advancements and Strategic Focus
- Intellia Therapeutics price target lowered to $50 from $90 at Truist
- Positive Outlook on Intellia Therapeutics: Buy Rating Supported by Financial Performance and Sector Alignment
- Intellia Therapeutics’ Promising Future: Buy Rating Backed by Strong Financials and Program Advancements
- Buy/Sell: Wall Street’s top 10 stock calls this week
Questions or Comments about the article? Write to editor@tipranks.com